Abstract
The results of a randomised trial of polyadenylic-polyuridylic acid given as adjuvant treatment for operable breast cancer were reviewed after a mean follow up period of 87 months. Of the 300 patients included in the original trial, 145 had been allocated to conventional treatment alone and served as controls. At the time of review the overall survival of the group given polyadenylic-polyuridylic acid was significantly improved (p less than 0.05) as compared with that of the controls given conventional treatment alone. Significant benefit (p less than 0.02) was also observed among patients with evidence of disease in lymph nodes, the best results occurring in those with up to three invaded nodes, who showed a significant increase in both overall and relapse free survival. No evidence of toxicity was recorded. These findings confirm the value of polyadenylic-polyuridylic acid as adjuvant treatment for operable breast cancer. Results in an experimental model and in patients receiving the adjuvant suggested a possible role of interferon and natural killer (NK) cells in the mechanism of action.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bonadonna G., Valagussa P., Rossi A., Tancini G., Brambilla C., Marchini S., Veronesi U. Multimodal therapy with CMF in resectable breast cancer with positive axillary nodes: the Milan Institute experience. Recent Results Cancer Res. 1982;80:149–156. doi: 10.1007/978-3-642-81685-7_25. [DOI] [PubMed] [Google Scholar]
- Donner M., Vaillier D., Lacour F. Changes in lymphocyte subpopulations in mice receiving a single injection of poly-A:U. Ann Immunol (Paris) 1977 Nov-Dec;128(6):1039–1052. [PubMed] [Google Scholar]
- Lacour J., Lacour F., Spira A., Michelson M., Petit J. Y., Delage G., Sarrazin D., Contesso G., Viguier J. Adjuvant treatment with polyadenylic-polyuridylic acid (Polya.Polyu) in operable breast cancer. Lancet. 1980 Jul 26;2(8187):161–164. doi: 10.1016/s0140-6736(80)90057-4. [DOI] [PubMed] [Google Scholar]
- Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rossi A., Bonadonna G., Valagussa P., Veronesi U. Multimodal treatment in operable breast cancer: five-year results of the CMF programme. Br Med J (Clin Res Ed) 1981 May 2;282(6274):1427–1431. doi: 10.1136/bmj.282.6274.1427. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Youn J. K., Hovanessian A. G., Riviere Y., Hue G., Lacour F. Enhancement of natural killer cell activity and 2-5A synthetase in mice treated with polyadenylic.polyuridylic acid. Cell Immunol. 1983 Jul 15;79(2):298–308. doi: 10.1016/0008-8749(83)90072-2. [DOI] [PubMed] [Google Scholar]
- Youn J. K., Lacour F., Hue G. Inhibition of C3H/He mouse mammary tumor growth by combined treatment with cyclophosphamide and polyadenylic-polyuridylic acid. Cancer Res. 1982 Nov;42(11):4706–4711. [PubMed] [Google Scholar]